Providers

Researchers retrospectively analyzed data from patients who visited 2 myeloma centers between March and October 2020, before vaccines were widely available but during large-scale implementation of regular screening processes.

Pegcetacoplan was approved by the FDA to treat geographic atrophy (GA), providing a treatment option for patients who previously had none, explained Eleonora Lad, MD, PhD, associate professor of ophthalmology, Duke University.

Results from the CLEAR Outcomes trial were presented today at the 72nd American College of Cardiology (ACC) Scientific Session Together With the World Congress of Cardiology. Plans for a broader label are in the works.

Seeking to speed up the execution of evidence-based care practices, the Patient-Centered Outcomes Research Institute (PCORI) announced the 42 health systems across the country who will join a 5-year program to build capacity and implementation to improve health care outcomes.

The 2 therapies, a 1-food and a 6-food elimination diet both used for eosinophilic esophagitis (EoE), were compared for outcomes after 6 weeks.

Outcomes from the loop diuretics were compared in this analysis, with study participants from the TRANSFORM-HF trial matched 1:1, all having been hospitalized for either do novo disease or worsening chronic disease.

On this episode of Managed Care Cast, we speak with Elizabeth Cuevas, MD, division chief of Allegheny Health Network’s (AHN) Center for Inclusion Health, on prevalent health inequities facing marginalized communities and strategies to identify and address these issues.

Utilizing real-world evidence that applies to the specific care needs of certain patient populations can promote timely decision-making among payers and providers on the use of effective cancer therapies available on the market, said panelists at the 2022 Patient-Centered Oncology Care® (PCOC) meeting.

Tochi M. Okwuosa, DO, Rush University Medical Center, discusses ways in which cancer treatments can adversely affect heart health outcomes for patients under the care of oncologists.

On this episode of Managed Care Cast, we speak with Simon F. Haeder, PhD, MPA, professor of public health at the Texas A&M University School of Public Health. He and his co-investigators looked at the accuracy of directories of psychiatrists and nonphysician mental health providers for all plans regulated by the California Department of Managed Health Care in 2018 and 2019.

At Patient-Centered Oncology Care®, Debra Patt, MD, PhD, MBA, of Texas Oncology, discussed managed care considerations that arise from the groundbreaking DESTINY-Breast04 study presented earlier this year.

A panel of experts discussed the explosion of information and advances in cancer genomics and the accompanying challenges of understanding the data and taking action.

Coverage from the January 18, 2023, Institute for Value-Based Medicine session with Regional Cancer Care Associates held in New Brunswick, New Jersey.

There are 2 ranibizumab biosimilars approved in the United States, and with more ranibizumab and the first aflibercept biosimilars on the horizon, gaps in knowledge among retinal physicians should be addressed.

An increased risk of hospitalization for more than 6 days due to community-acquired infections was associated with male sex and admittance to the Pulmonology or Surgery department, with risk shown to differ according to pathogen.